Bruce Mitchell
Bruce Mitchell has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Adele Barnard
1 shared publication- Alexios G. Carayannopoulos
Department of Physical Medicine and Rehabilitation, Rhode Island Hospital, Brown University Medical School, Providence, RI, USA
1 shared publication - Antoine G. Tohmeh
MultiCare Neurosurgery and Spine, Spokane, USA
1 shared publication - Ashish Gulve
Department of Anesthesiology and Pain Management, James Cook University Hospital, Middlesbrough TS4 3BW, UK
1 shared publication - Christopher A. Gilmore
Center for Clinical Research, Winston Salem, NC, USA
1 shared publication - Christopher Gilligan
Robert Wood Johnson University Hospital, New Brunswick, NJ, USA
1 shared publication
Latest Publications
- Open Access
- 9 March 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (10) , 2486-2498
An implantable restorative-neurostimulator for refractory mechanical chronic low back pain: a randomized sham-controlled clinical trial
Chronic low back pain can be caused by impaired control and degeneration of the multifidus muscles and consequent functional instability of the lumbar spine. Available treatment options have limited effectiveness and prognosis is unfavorable. We conducted an international randomized, double-blind, sham-controlled trial at 26 multidisciplinary centers to determine safety and efficacy of an implantable, restorative neurostimulator designed to restore multifidus neuromuscular control and facilitate relief of symptoms (clinicaltrials.gov identifier: NCT02577354). Two hundred four eligible participants with refractory mechanical (musculoskeletal) chronic LBP and a positive prone instability test indicating impaired multifidus control were implanted and randomized to therapeutic (N = 102) or low-level sham (N = 102) stimulation of the medial branch of the dorsal ramus nerve (multifidus nerve supply) for 30 minutes twice daily. The primary endpoint was the comparison of responder proportions (≥30% relief on the LBP visual analogue scale without analgesics increase) at 120 days. After the primary endpoint assessment, participants in the sham-control group switched to therapeutic stimulation and the combined cohort was assessed through 1 year for long-term outcomes and adverse events. The primary endpoint was inconclusive in terms of treatment superiority (57.1% vs 46.6%; difference: 10.4%; 95% confidence interval, −3.3% to 24.1%, P = 0.138). Prespecified secondary outcomes and analyses were consistent with a modest but clinically meaningful treatment benefit at 120 days. Improvements from baseline, which continued to accrue in all outcome measures after conclusion of the double-blind phase, were clinically important at 1 year. The incidence of serious procedure- or device-related adverse events (3.9%) compared favorably with other neuromodulation therapies for chronic pain.
- 9 March 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (10) , 2486-2498
Open AccessAn implantable restorative-neurostimulator for refractory mechanical chronic low back pain: a randomized sham-controlled clinical trial
Chronic low back pain can be caused by impaired control and degeneration of the multifidus muscles and consequent functional instability of the lumbar spine. Available treatment options have limited effectiveness and prognosis is unfavorable. We conducted an international randomized, double-blind, sham-controlled trial at 26 multidisciplinary centers to determine safety and efficacy of an implantable, restorative neurostimulator designed to restore multifidus neuromuscular control and facilitate relief of symptoms (clinicaltrials.gov identifier: NCT02577354). Two hundred four eligible participants with refractory mechanical (musculoskeletal) chronic LBP and a positive prone instability test indicating impaired multifidus control were implanted and randomized to therapeutic (N = 102) or low-level sham (N = 102) stimulation of the medial branch of the dorsal ramus nerve (multifidus nerve supply) for 30 minutes twice daily. The primary endpoint was the comparison of responder proportions (≥30% relief on the LBP visual analogue scale without analgesics increase) at 120 days. After the primary endpoint assessment, participants in the sham-control group switched to therapeutic stimulation and the combined cohort was assessed through 1 year for long-term outcomes and adverse events. The primary endpoint was inconclusive in terms of treatment superiority (57.1% vs 46.6%; difference: 10.4%; 95% confidence interval, −3.3% to 24.1%, P = 0.138). Prespecified secondary outcomes and analyses were consistent with a modest but clinically meaningful treatment benefit at 120 days. Improvements from baseline, which continued to accrue in all outcome measures after conclusion of the double-blind phase, were clinically important at 1 year. The incidence of serious procedure- or device-related adverse events (3.9%) compared favorably with other neuromodulation therapies for chronic pain.
- 1 May 2011
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 43 (5) , 138
Prolotherapy For Sacro-iliac Joint Pain: Reduction In Pain And Increases In Strength
- 1 May 2011
- Published by Wolters Kluwer Health in Medicine & Science in Sports & Exercise
- Vol. 43 (5) , 138
Prolotherapy For Sacro-iliac Joint Pain: Reduction In Pain And Increases In Strength